BRIEF-Zealand Pharma announces new timelines for U.S. FDA decision on iglarlixi

* Zealand announces new timelines for a U.S. FDA decision on iglarlixi, the fixed-ratio combination of lixisenatide (adlyxintm) and lantus(r), for the treatment of type 2 diabetes